Purpose: Pre‐treatment patient repositioning in highly conformal radiotherapy modalities is a prerequisite for reducing setup uncertainties. A MVCT image set has to be acquired to account for daily changes in the patient's internal anatomy and setup position. This study aims to investigate the expected effect of patient setup correction with the Hi‐Art tomotherapy system by using radiobiological measures. Method and Materials: Using the Planned Adaptive module (tomotherapy, Inc, Madison, WI), eventual dose discrepancies can be evaluated and corrected. In this study, patients treated for lung, pancreas and prostate carcinomas by Helical Tomotherapy plans are evaluated. In each cancer case, two dose distributions with and without patient setup correction were calculated using the MVCT image sets and they were evaluated using the complication‐free tumor control probability (P+) and biologically effective uniform dose (BEUD) concepts. Results: For the lung cancer case, at the optimum dose levels of the two dose distributions, the P+ value is 57.6% and 56.8% for a BEUDITV of 64.8 Gy, respectively. The respective total control probabilities, PB are 78.1% and 78.1%, whereas the corresponding total complication probabilities, PI are 20.5% and 21.3%. For the pancrease cancer case, the P+ value is 95.0% for a BEUDITV of 67.9 Gy and 97.5% for a BEUDITV of 69.9 Gy, respectively. The respective PB values are 97.8% and 98.7%, whereas the PI values are 2.9% and 1.2%. For the prostate cancer case, the P+ value is 57.7% for a BEUDITV of 90.2 Gy and 55.9% for a BEUDITV of 90.6 Gy, respectively. The respective PB values are 83.7% and 84.7%, whereas the PI values are 26.1% and 28.8%. Conclusion: According to our results, patient setup corrections during registration are adequate to produce the necessary target localization. Clinical cases, which look dosimetrically similar, can be quite different in radiobiological terms.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging